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ABSTRACT
The central pathological feature of Alzheimer’s disease (AD) is the sequential 
proteolytic processing of amyloid precursor protein (APP) to amyloid-β peptides 
(Aβ) agglomeration. The clearance of Aβ may be induced by the large zinc-binding 
protease insulin degrading enzyme (IDE). IDE is the common link between AD 
and Type II diabetes as insulin is an IDE target as well. Not surprisingly, the 
search for safe and effective drugs modulating IDE is ongoing. A new pregnancy 
derived peptide, PreImplantation Factor (PIF), inhibits neuro-inflammation and 
crosses the blood-brain-barrier. Importantly, we report that the (R3I4K5P6) core 
sequence of the PIF peptide modulates IDE function and results in decreased Aβ 
agglomeration in neuronal cells. Using bioinformatics we show that PIF binds to 
the IDE complex and sterically competes for the same place as insulin or Aβ. The 
predicted RIKP sequence and especially the specific I4 and P6 amino acids are 
essential for hydrophobic interactions with the IDE complex. In terms of potential 
AD treatment, PIF was successfully tested in neurodegenerative animal models 
of perinatal brain injury and experimental autoimmune encephalitis. Importantly, 
sPIF received a FDA Fast Track Approval and orphan drug designation for first-in-
human trial in autoimmunity.
INTRODUCTION
Sequential proteolytic processing of amyloid 
precursor protein (APP) leads to amyloid-β peptides 
(Aβ) agglomeration, the central pathological feature of 
Alzheimer’s disease (AD) [1, 2]. Development of effective 
and safe disease modifying treatments that directly target 
AD pathology is a priority especially as the drugs currently 
available for AD only manage symptoms and do not target 
Amyloid plaques [3]. A potential target is the large zinc-
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binding protease insulin degrading enzyme (IDE) as IDE 
is involved in clearance of insulin and Aβ [2, 4]. Multiple 
authors postulate that IDE is the common link between 
AD and Type II diabetes [2, 5, 6]. For example, decreased 
IDE expression was reported in AD patients [7] and IDE 
polymorphisms were associated with impaired insulin 
metabolism [8]. Chemical IDE inhibitors improve insulin 
activity [9] while IDE activators regulate Aβ formation 
in neurons [2, 10]. Finally, the increase in a given IDE 
variant reduces circulating Aβ levels, while other variants 
promote the disease [11, 12]. Together, targeting IDE is an 
attractive strategy to prevent AD and type II diabetes but 
safe and potent drugs are currently lacking [2].
Recently, a new pregnancy derived peptide emerged 
in the arena of neurotherapeutics. PreImplantation Factor 
(PIF) can be detected in the maternal circulation during 
pregnancy [13, 14] and its presence has been correlated 
with live birth [14–16]. PIF has been implicated in 
promoting embryo implantation through modulating 
maternal immune tolerance [14, 17–19]. Consistent with 
the immunomodulatory function, a synthetic PIF analog 
(sPIF) was able to reverse and prevent paralysis and 
restore myelination through inhibiting neuro-inflammation 
in murine models of experimental autoimmune 
encephalomyelitis [20, 21]. The neuroprotective property 
of sPIF was further underscored by its ability to mitigate 
neuronal loss and microglial activation in murine model 
of immature brain injury [22, 23]. Here we report that the 
(R
3
I
4
K
5
P
6
) core sequence of PIF modulates IDE function 
and results in decreased Aβ agglomeration in neuronal 
cells. This is in line with PIF`s pleiotropic function both in 
pregnancy and in non-pregnant setting [24]. Additionally, 
preclinical studies identified a synthetic analog of PIF 
(sPIF) as an effective drug in autoimmune diabetes [25], 
atherosclerosis [26], graft versus host disease [27], and 
radiation induced pathology [28]. In terms of potential 
AD treatment, sPIF crosses the blood-brain barrier and 
was successfully tested in neurodegenerative animal 
models of perinatal brain injury [22, 23] and experimental 
autoimmune encephalitis [20, 21]. Importantly, sPIF 
received a FDA Fast Track Approval for first in human 
trial in autommune hepatitis.
RESULTS
PIF reduces Aβ in IDE dependent manner
In order to evaluate PIF-IDE interactions in the 
context of AD we stably transfected neuronal cells 
(N2a) cells with human APP695 (APP-N2a) to increase 
endogenous APP levels first [29]. Notably, this setup 
represents an in-vitro AD model as sequential proteolytic 
processing of APP results in Aβ formation and Aβ is an 
IDE target. We treated cells with sPIF and indeed such 
treatment decreased Aβ formation while increasing IDE 
levels significantly (Figure 1A and 1B compare red and 
green bars). Importantly, in the presence of the IDE 
inhibitor N-ethylmaleimide (NEM) abolished the sPIF 
induced effects confirming PIF-IDE interaction.
The RIKP sequence participates in PIF-IDE 
interaction
To further dissect the PIF-IDE interactions we 
retrieved molecular models corresponding to the 10 PIF 
targets obtained by experimental methods (ProteoArray 
and proteomics) and their homologous protein 
family members. Using Protein Data Bank (PDB) we 
extracted about 200 crystallography generated PDBs 
corresponding to the positive protein hits and more than 
2500 crystallography generated PDBs corresponding 
to the negative protein hits and discarded the redundant 
ones to 60 and 2369 accordingly (see Supplementary 
Table 1). Using STRALCP (STRucture ALignment-
based Clustering of Proteins) algorithm we identified 
multiple distinct protein families sharing a common 
structural “pattern” (Figure 1C). We determined the 
statistical probability of important residues resulting in 
the identification of M*RIKP**** amino sequence with 
the predicted small sequence (RIKP) likely to participate 
in peptide/protein interactions. PepSite had 95.24% true 
positive detection rate in PDBs corresponding to PIF 
positive targets identified using ProteoArray, while the 
PDBs corresponding to the negative targets available in 
the rest of the protein array had 40.33% false positive 
score (Figure 2A) [30]. Indeed, R3 and K5 seem to be 
most promising positive hits followed by the A9 and N10. 
Together, we identified the RIKP sequence as the most 
commonly participating in potential PIF-IDE interaction 
matching the R3*K5****N10 signature.
PIF sterically competes for the same binding site 
as insulin or Aβ
Given the predicted RIKP signature of PIF, we 
aimed to identify the potential and specific amino acid 
interaction sites with IDE next. Notably, IDE has two 
principal forms [31] with closed form (IDEC) having 
minimal while the open form (IDEO) having high catalytic 
activity [32]. IDE is activated by ATP to degrade short 
peptides such as Aβ or insulin by a change in enzyme 
conformation to IDEO [33]. We predicted the putative 
binding sites of PIF using PepSite2 server and then the 
de novo modeled PIF was docked to crystallographic 
models of IDE in open ligand bound and closed ligand 
free state (FlexPepDock flexible docking server). Indeed, 
the PIF-IDE complex acquires its highest energy gain 
when PIF is bound to IDEO compared to IDEC (Figure 
2B). Importantly, PIF-IDEO complex forms high affinity 
bond in Aβ and insulin presence (Figure 2C). The distance 
of PIF from the binding pocket increases when Insulin 
is present in order to maintain stable molecular complex 
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(Figure 2C and 3A). This suggests that PIF sterically 
competes for the same place as insulin. We can replicate 
this in case of excessive Aβ bound to IDE as well, where 
similarly PIF and Aβ/Amylin is bound to the very same 
pocket (Figure 2C and 3A). Interestingly, PIF binding 
Energy is even stronger when open IDEO conformation 
has already attached Aβ or Amylin. Stabilization of the 
molecular complex occurs only when PIF is repulsed back 
to 4 Å distance. Theoretically, PIF is less prone to bind 
IDE-Aβ than IDE-Insulin, but still it forms high affinity 
bond despite Aβ presence, when compared to free IDEC 
conformation. Together, PIF binds to the IDEO complex 
and sterically competes for the same place as insulin 
or Aβ.
Figure 1: PIF reduces Aβ formation in IDE dependent manner and targets distinct protein families. (A) Representative 
Western Blots of Aβ and IDE in neuronal cells after APP transfection. (B) sPIF reduces Aβ formation in IDE dependent manner. (C) 
Identified regions of structural similarity within the set of protein structures by STRALCP. Clustering of structurally conserved fragments 
(left). STRALCP identified structural similarity between selected “reference” structure and other analyzed structures, represented as colored 
bars, based on C
alpha
 - C
alpha
 distance deviation at each position between the reference (top bar) and other structures (right). The colors 
indicate RMSD between aligned residues, ranging from green (below 2Å), yellow (below 4Å), orange (below 6Å), to red (above 6Å). 
STRALCP: STRucture ALignment-based Clustering of Proteins; RMSD: Room mean square distances; Aβ: Amyloid Beta; IDE: Insulin 
degrading enzyme; APP: Amyloid precursor protein; sPIF: synthetic PreImplantation Factor; * p<0.05; ** p<0.01; *** p<0.001 (ANOVA 
followed by two tail t test). In-vitro experiment results represent at least three independent experiments.
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The RIKP sequence (I4 and P6) are essential for 
PIF-IDE interaction
To further dissect the importance of individual 
amino acid residues in PIF sequence, we generated 
putative PIF mutants (PIFmut) using BeatMusic server 
for in silico mutagenesis (Supplementary Figure 1). For 
further analysis we selected PIF
mut1
 (mutation P
6
 to E
6
) 
which was specific for the active form of IDE and having 
the highest change in Energy of binding (Figure 3C, 
4A). The second mutant was PIF
mut3
 (I
4
 to G
4
) which was 
predicted to disrupt the binding with chain B of active IDE 
while affecting both chains in the IDE closed conformation 
(Figure 3C, 4A). In order to provide further evidence that 
PIF unique amino acid structure is responsible for specific 
PIF-IDE interactions we stably transfected neuronal cells 
with human APP695 (APP-N2a) again. Indeed, PIF
mut1 and 3
 
treatments did not decrease Aβ formation as efficient 
as sPIF (Figure 3B). We further re-docked the in silico 
estimated PIF mutants (PIF
mut1
and PIF
mut3
). The docking/
binding models visually confirmed that PIF
mut1
 (P
6
 to E
6
) is 
shifted out of the wild type binding pocket (distance cutoff 
4.5 Å), while PIF
mut3
 (I
4
 to G
4
) is completely removed 
from the pocket and rather binds different set of IDE AA 
Figure 2: The Arg-Ile-Lys-Pro (RIKP) sequence participates in the PIF targets interaction and sterically competes 
for the same binding site as insulin or Aβ. (A) Prediction of PIF peptide:protein binding interface with putative PIF:target binding 
residues interaction of ProtoArray® true positive and negative. We determined the statistical probability of important residues and identified 
the M*RIKP**** sequence to be most likely binding pattern. Red squares are for a hit, blue or white are for a miss while blue is in the 
region of positive hits, and the white is in the region of negative hits. (B and C) Cartoons representing the flexible in silico peptide-protein 
docking (FlexPepSite) of PIF to IDE. (B) PIF interacts with IDE (in both open and closed conformation) but has the higher Energy in open 
conformation. (C) PIF binds to IDE (open conformation) in combination with Aβ or Insulin with lesser Energy than to IDE alone. Energy 
is measured in Rosetta Energy Unit (REU). Aβ: Amyloid Beta; IDE: Insulin degrading enzyme; PIF: PreImplantation Factor.
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residues (Figure 3C and 3D). Generally, both mutants have 
lower probability and higher distance from IDE grove and 
less favorable energy profile to bind to IDEO in presence 
of AD as shown using in silico docking binding interface 
determined by interacting residues form PIF and IDE 
(Figure 4A).
The I4 and P6 amino acids participate in 
hydrophobic interactions of the PIF-IDE 
complex
Finally, we determined to examine the structure-
function relationship and exposed IDE in cell free 
environment (recombinant enzyme) to synthetic PIF. We 
used Differential Scanning Fluorimetry (DSF) to identify 
low-molecular-weight ligands that bind and stabilize 
purified proteins. Notably, we used a fluorescent dye-
based probe that preferentially binds the hydrophobic 
regions of a protein, which are increasingly exposed 
during protein denaturation. Therefore, a ligand bound 
to a protein, e.g. to its active site, has the propensity to 
increase its thermal stability (and hence it’s Tm) through 
newly formed ligand-protein interactions allowing 
prospective binding ligand-affinity assessment [34]. We 
detected only PIF
wt
 to bind effectively to the protein 
target (Figure 4A right panel) while the PIF
mut1
 showed 
Figure 3: PIF competes with Insulin and Aβ for binding to IDE, but it binds to distinct sites. (A) Flexible peptidein silico 
docking of PIF to crystallography models of IDE in a complex with Insulin or with Aβ/Amylin, based on predicted binding site. Pink mesh 
shows PIF (in red) binding region. Blue represents Insulin and yellow Aβ or Amylin. (B) Representative Western Blots of Aβ in neuronal 
cells, after APP transfection, treated with sPIF and PIF
mut1 and 3
. (C) CABS Dock blind in silico docking of flexible PIF peptide (red) to IDE 
based on molecular dynamics. Binding interface is determined by interacting PIF AA residues with IDE, defined as PIF AA versus IDE AA. 
This is reflected as a shift of the putative binding interface (distance cutoff 4.5 Å) from deeper to more superficial AA residues in the PIF 
binding groove. This algorithm does not use PepSite2 predicted binding spots but rather scans IDE for binding affinity blindly. The docking/
binding models visually confirm that the PIF
mut1
 is shifted out of the wild type binding pocket, while the PIF
mut3
 is completely removed from 
the pocket and rather binds by different set of IDE AA residues. (D) Flexible peptidein silico docking of PIF and PIF
mut1 and 3
 to crystallography 
models of IDEO in a complex with Aβ/Amylin, based on predicted binding site. Red (PIF), orange (PIF
mut1
), and blue (PIF
mut3
) meshes show 
binding regions in the presence of Aβ/Amylin (yellow).Aβ: Amyloid Beta; IDE: Insulin degrading enzyme; IDEC / O: Insulin degrading 
enzyme in closed or open confirmation; PIF: PreImplantation Factor; Con: Control. **p<0.01 (ANOVA followed by two tail t test). In-vitro 
experiment results represent at least three independent experiments. two-tailed Student’s t-test and results are presented mean + SD.
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Figure 4: Flexible in silico docking of PIF
wt
 versus PIF
mut1
 and PIF
mut3
. (A) The binding Energies correspond to binding affinity 
and are in line with Differential Scanning Fluorimetry data (right panel), demonstrating that PIF
mut1
 has a reduced binding affinity and 
thermal shift (ΔTm). This results in a weaker PIF
mut1
 binding to IDE (hence lower stabilization of the IDE energy). PIF
mut3
 has also lower 
binding affinity to the site of PIF
wt
 binding, but its ligand-receptor interaction validation demonstrated slight positive melting shift, and 
increase of IDE stabilization energy, suggesting increased affinity to IDE. Binding models RMSD suggest displacement of PIF from its 
natively predicted binding site upon mutagenesis. Similarly, Chimera visualizations of the docking models confirm this location shift 
out of the groove (left cartoons). (B) Planar schemes of PIF
wt/mut-1/mut-3
-IDE interface bindings. In the upper panels, we demonstrate that 
the PIF
wt
 C-terminus binds Gly101 or Ser100. When mutated (loss of Pro6: PIF
mut-1
) PIF binding sites change such as Ala97 or Gly323. 
Together, this results in a shift in the binding site upwards of the groove (left panels). The loss of Ile4 (PIF
mut-3
) causes a similar shift in 
the IDE binding residues, but with increasing the probability of binding to Ala97, His65, or Pro171. Binding mechanics of PIF to IDE 
suggests that PIF
mut-1
 disrupts the interface by losing hydrogen bonds, while PIF
mut-3
 although predicted as lowering affinity, gains more 
hydrophobic interactions. As demonstrated in the lower panels, the binding mechanics to IDE includes both hydrogen bonds (lines with 
distance in Å) and hydrophobic contacts (red “eyelash”). With blue lines—PIF chemical bonds, in green—IDE residues participating in 
the interface, all residues shared between PIF
wt
 and PIF
mut-1/3
 are circled in red. The models confirm that PIF
mut-1
 has fewer hydrogen bonds 
and hydrophobic interacting residues, while PIF
mut-3
 displays increasing hydrophobic interacting residues. Aβ: Amyloid Beta; IDE: Insulin 
degrading enzyme; IDEC / O: Insulin degrading enzyme in closed or open confirmation; PIF: PreImplantation Factor.
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reduced binding affinity and decreased ΔTm. In contrast, 
we detected minimally increased affinity of binding 
measured as positive ΔTmin PIFmut3. In order to determine 
the specific reason why the PIFmutants displayed reduced 
ΔTm or disrupted ΔGinterface, we generated planar schemes of 
PIF-IDE interface binding (Figure 4B). Interestingly, we 
detected loss of multiple hydrogen bonds and hydrophobic 
interactions in PIF
mut1
 compared to PIF
wt.
. Although PIF
mut-3
 
lost as many hydrogen bonds as PIF
mut-1
, we detected 
increased hydrophobic interacting residues when “sliding 
out” of the natural groove (Figure 4A and 4B). PIFmutants 
predominantly bind closer to N-terminus amino acid 
residues of the IDEO chain. The PIF
wt
 C-terminus binds 
Gly101 or Ser100 (Figure 4B). When mutated (loss of 
Pro6: PIF
mut-1
) PIF binding sites change such as Ala97 or 
Gly323. Together, this results in a shift in the binding site 
upwards of the groove. The loss of Ile4 (PIF
mut-3
) causes 
a similar shift in the IDE binding residues, but with 
increasing the probability of binding to Ala97, His65, 
or Pro171. Together, the predicted RIKP sequence and 
especially the specific I4 and P6 amino acid location are 
essential to for hydrophobic interactions with the IDEO 
complex.
DISCUSSION
We provide evidence that PIF multi-targeting 
interaction with IDE is exerted through the (R
3
I
4
K
5
P
6
) 
core sequence. This is of importance given PIF as an 
evolutionary conserved peptide exerting pleiotropic 
functions such as immune regulatory and neuroprotective 
properties [24]. The amino acid core sequence itself will 
not explain the binding to different targets with their 
associated effects. However, it provides evidence that 
PIF induces peptide/protein interactions that may be 
structurally and functionally unrelated but they share local 
structural similarities. For example, the binding region of 
PIF to IDE is highly similar to that of protein disulfide 
isomerases (PDI) and heat shock protein 70 (HSP70), 
which are both PIF targets [30]. Therefore, the flexible 
PIF peptide binds to specific target protein “pockets” 
and modulates their interaction and specific function. 
The specific RIKP structure is of importance as the 
docking analysis comparing PIF
wt
 to PIFmutants displayed 
(Figures 3 and 4). Further, PIF may rather (or in addition) 
stabilize the IDE in the open conformation, and make its 
active pocket more accessible to substrates. At least four 
factors contribute to the unique mechanism of substrate 
recognition by IDE [4].
One factor contributing to the substrate recognition 
is the proper anchoring of the cleavage site in the catalytic 
cleft. As seen in the Binding Interface Contact Map 
(Figure 3B, right panel), PIFmutants predominantly bind 
closer to N-terminus amino acid residues of the IDEO 
chain. The PIF
wt
 C-terminus will bind Gly101 and Ser100 
(Figure 4B). When mutated (loss of Pro6: PIF
mut-1
) or loss 
of Ile4 (PIF
mut-3
), PIF targets change and results in a shift 
in the binding site upwards of the groove. Therefore, the 
PIF core sequence is one factor determining PIF-IDE 
interaction. The other factor is the IDE binding pocket. 
The PIF-IDE effects are induced due to competition for 
the same IDE pocket binding site as insulin or Aβ. The 
factor determining which peptide will bind to IDE are 
the hydrogen bonds (Figure 4B and 4C). PIF
wt
 do not 
have significant positive charges at the C-termini and 
therefore avoids the charge repulsion from IDEO. This 
is especially true in comparison to other IDE-substrate 
structures such as insulin, Aβ, or Amylin (Figure 3A) 
where PIF sterically competes for the same binding site. 
Multiple other substrates such as brain natriuretic peptide, 
glucagon-like peptide and insulin growth factor I have 
many positively charged residues at their C termini and are 
poor IDE substrates [4]. Therefore, PIF effects would be 
less evident. By contrast, substrates, which lack positive 
charges at their C termini are excellent IDE substrates 
and could represent a potential PIF target. These include 
the related hormones atrial natriuretic peptide, glucagon, 
and IGF-II but the PIF potential interactions with these 
peptides are beyond the scope of this manuscript.
At last, the size is an important contributor. The 
IDE catalytic chamber is large enough to accommodate 
only relatively small peptides (estimated to be <50 
amino acids) [4]. As an M16A member of the Zn2+-
metalloprotease family, IDE has a buried catalytic site in 
the structure and the closed–open conformational switch 
kinetically controls access to this chamber. Therefore, 
the self-oligomerization may allosterically regulate the 
catalytic activity of IDE and represents the advantage 
of a small molecule like PIF. Not surprisingly, a large 
number of chemical modulators of IDE activity such 
as chelators, divalent cations, thiol-blocking agents, 
curcumin, docosahexaenoic acid, or sevoflurane were 
identified. However, their use as therapeutic agents is 
limited due to low potency, non-selectivity and/or highly 
toxicity [2]. Importantly, the IDE dependent reduction of 
Aβ agglomeration in neuronal cells (Figure 1A and 1B) by 
PIF is in line with previous neuroprotective effects [24], 
which supports PIF use in AD.
The use of PIF in AD is supported by the fact that 
sPIF crosses the blood-brain barrier and was successfully 
tested in neurodegenerative clinically relevant models 
of perinatal brain injury [22, 23] and experimental 
autoimmune encephalitis [20, 21]. We are not providing 
here in-vivo data supporting the use of PIF in AD, which 
is a limitation of our study. Animal models of AD are 
currently being prepared but are beyond the scope of this 
manuscript. However, sPIF received a FDA Fast-Track 
Approval for first-in-human Phase I trial and orphan drug 
designation for autoimmunity, which was successfully 
completed [35]. Such observations together with the 
current evidence support PIF’s potential protective role in 
AD or type II diabetes, where IDE plays a major role.
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MATERIALS AND METHODS
PIF peptide synthesis
Synthetic PIF (MVRIKPGSANKPSDD), 
scrambled (inactive PIF) GRVDPSNKSMPKDIA and 
mutated PIF I4 to G4 (MVRGKPGSANKPSDD) or P6 
to E6 (MVRIKEGSANKPSDD) were produced using 
solid-phase peptide synthesis (Peptide Synthesizer, 
Applied Biosystems, Foster City, CA, USA) employing 
Fmoc (9-fluorenylmethoxycarbonyl) chemistry. Final 
purification was carried out by reverse-phase high-
pressure liquid chromatography (HPLC), and peptide 
identity was verified by mass spectrometry. Alexafluor 
647-PIF conjugate was generated (Bio-Synthesis, Inc., 
Lewisville, TX, USA). N-Ethylmaleimide was obtained 
from Sigma-Aldrich, St Louis MO, USA.
STRALCP (STRucture ALignment-based 
clustering of proteins)
Protein classification is essential for proper protein’s 
structure, function and interaction with other proteins 
prediction. Although sequence similarities correspond 
to structure similarities most of the time, structural 
similarity, however, does not necessarily correspond to 
sequence similarity [36]. Thus, structural comparison and 
classification allows for structure and function prediction 
for uncharacterized proteins, and in our case finding 
common ground for multiple targets of same short PIF 
peptide ligand. STRALCP identifies regions of structural 
similarity within a given set of protein structures and 
uses those regions for hierarchical clustering. STRALCP 
generates detailed information about global and local 
similarities between pairs of protein structures, identifies 
fragments (spans) that are structurally conserved among 
proteins, and uses these spans to group the structures 
accordingly. Color coded bars based on structural 
similarity and cluster maps between the referent PDB 
structure and all others are produced by the server. We 
used the PDB IDs from PDB databank corresponding to 
the previously identified by ProteoArrayTM targets of PIF. 
As each PIF protein target had multiple crystallography 
PBDs corresponding to it, a preliminary redundancy 
discarding step was carried out first. The parameters fed 
to the Local-Global Alignment (LGA) scoring algorithm 
were option “-4-sia” (searching for residue-residue 
correspondence, where the best superposition is calculated 
completely ignoring sequence relationship between 
reference and compared proteins, and the suitable amino 
acid correspondence (structural alignment) is reported) 
[36]. Thus, STRALCP lead to understanding the structural 
similarity of common PIF targets and derive conclusions 
for shared modes of PIF actions and its interaction with 
other molecules. We used the following web server at 
http://proteinmodel.org/AS2TS/STRALCP/ for selecting 
protein structures, calculating structurally conserved 
regions and performing automated clustering [37].
In silico modeling of the PIF binding to protein 
targets
PepSite 2 server (http://pepsite2.russelllab.org/) 
was used for in silico prediction of PIF peptide binding 
sites on protein surfaces, referred hereon as PepSite only. 
As PepSite server is limited to 10 amino acids (aa) for 
peptide sequence, only the first 10 aa were used, as it was 
shown previously that the first 9 aa are shared between 
the two biologically active PIF forms, both having the 
same actions [38]. PepSite was used in two different 
manners: 1). in an automated workflow governed by the 
Taverna bioinformatics workflow framework, to query 
all PDBs corresponding to PIF positive and negative 
targets (from ProteoArrayTM) using REST service, taking 
into account the top scored replies (PDB selection is 
described in STARLCP method). Then the ranked tuples 
of PIF peptide binding sites, PepSite binding Score and 
p-value of binding prediction, were all used to categorize 
the different positive and negative targets and generate 
enrichment statistics using positional partial cumulative 
probability scores. Secondly, PepSite was also used in 
in silico validation studies, where PIF predicted position 
(defined as geometric centers of amino acid residues) of 
binding to IDE was used to further flexible dock PIF
wt
 
and PIFmutants to IDE open and closed forms using Rossetta 
FlexPepDock (see below). In PepSite predicted binding 
to positive/negative PIF targets, p-Value defined the 
probability of erroneous binding. Additionally, the ranking 
of the targets and the Partial Cumulative Probability were 
calculated using 1-p-Value Probability of true binding, 
divided to 10 (as the number of AA in PIF sequence used 
by PepSite) and also divided by the number of PDBs in 
each tested group.
Rosetta FlexPepDock server
Rosetta FlexPepDock server (http://flexpepdock.
furmanlab.cs.huji.ac.il/) for high-resolution peptide 
docking was used as well. We used as input a PDB 
file consisting of the PIF protein target as a first chain: 
Insulin degradation enzyme, PDB models 2WBY (crystal 
structure of IDE in complex with Insulin) and 2JG4 
(crystal structure of substrate-free IDE in its closed 
conformation) and PIF peptide conformation predicted 
ab initio using the Pep-Fold server (http://bioserv.rpbs.
univ-paris-diderot.fr/PEP-FOLD/) as a second chain. The 
peptide location was derived from the binding prediction 
obtained using PepSite 2. Notably, FlexPepDock allows 
full flexibility to the peptide and side-chain flexibility to 
the target protein. Thus, it provides accurate refinement 
of the peptide structure, starting from up to 5.5A RMSD 
(root-mean-square deviation (RMSD) is the measure 
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of the average distance between the atoms (usually the 
backbone atoms) of superimposed proteins) of the native 
conformation [39].
All protein image rendering and the multiple 
sequence alignment (MSA) following multiple protein 
structural alignment (superposition) was performed using 
Chimera v.1.8c (UCSD, US). A local Smith-Waterman 
alignment algorithm, BLOSUM 35 matrix, 80-90% 
secondary structure score inclusion, and 3 A iterative 
matching, were all used for the structural alignments. 
MSA was performed using superposition and circular 
permutation, with residue-residue distance cutoff of 5Å. 
MultiProt server (http://bioinfo3d.cs.tau.ac.il/MultiProt/) 
was used for partial multiple alignment of the protein 
targets identified by ProtoArray®, using algorithm for local 
multiple structural alignment of common geometrical 
cores [40].
CABS-dock server
CABS-dock serverperforms blind flexible protein-
peptide docking by searching for the binding site, allowing 
for full flexibility of the peptide and small fluctuations 
of the receptor backbone. The blind docking generates 
peptide model and carries out molecular dynamics of 
the receptor while searching for binding space. First 
random structures of the peptide are generated and 
randomly placed on the surface of the sphere centered at 
the receptor’s geometrical center then Replica Exchange 
Monte Carlo molecular dynamics with 10 replicas 
uniformly spread on the temperature scale is utilized. 
Additionally, the temperatures of the replicas constantly 
decrease as the simulation proceeds to end on the bottom 
of the energy minima. On output the procedure produces 
10 trajectories (one for each replica), each consisting of 
1000 time-stamped simulation snapshots for a combined 
total of 10,000 models. During the simulation, the receptor 
molecule is kept in near-native conformations by a set 
of distance restraints binding pairs of C-alpha atoms. 
Selection of the final representative models follows a 
two-step procedure: Initial filtering of the 10 trajectories, 
excluding all unbound states. Selected models (1000 in 
total) are clustered together in the k-medoids procedure 
down to 10 final models. This algorithm allows for 
selection of docking models without prior knowledge of 
the peptide binding site. Additionally, regardless of the 
rigid docking approaches, a molecular dynamics ensures 
fluctuation of the receptor and full plasticity of the binding 
ligand [41]. CABS-dock web server for the flexible 
docking of peptides to proteins without prior knowledge 
of the binding site [41].
LigPlot+
LigPlot+was used for automatic generation of 
schematic diagrams of protein-ligand interactions for 
a given ligand in a PDB file. The software is based on 
LIGPLOT and DIMPLOT and allows for flattened view 
of the PIF interaction upon in silico docking. Additionally, 
related LIGPLOTs superposing highlight similarities and 
differences between related proteins binding the same/
similar ligand, or the same/similar ligand binding to 
different proteins. LigPlot+ attempts, as best it can, to 
place residues in the new plot on top of the equivalent 
residues in the old one.
Differential scanning fluorimetry (DSF)
Differential scanning fluorimetry (DSF) is a 
method used to identify low-molecular-weight ligands 
that bind and stabilize purified proteins. The temperature 
at which a protein unfolds is measured by an increase in 
the fluorescence of a dye with affinity for hydrophobic 
parts of the protein, which are exposed as the protein 
unfolds. A simple fitting procedure allows quick 
calculation of the transition midpoint; the difference 
in the temperature of this midpoint in the presence 
and absence of ligand is related to the binding affinity 
of the small molecule, which can be a low-molecular-
weight compound, a peptide or a nucleic acid. DSF 
monitors thermal unfolding of proteins in the presence 
of a fluorescent dye and is typically performed by 
using a real-time PCR instrument [34]. The thermal 
shift assays were conducted on an Mx3005P from 
Stratagene, originally designed for real-time quantitative 
PCR. The system contains a heating/cooling device for 
accurate temperature control, a 488 nm argon-ion laser 
excitation source, a dual-axis synchronous scanning 
head to distribute the excitation light to the 96 wells 
of a microplate, a spectrograph, and a charge-coupled 
device camera for the fluorescence detection from 500 
to 600 nm. It permits then the simultaneous imaging 
of the fluorescence changes in the microplate recorded 
using MXP software (Stratagene, La Jolla, CA). DSF 
analysis protocol followed the Guidelines issued by the 
Structural Genomics Consortium at Oxford University 
for Compound Screening [34].
Thermal stability measurements were recorded 
in 96-well PCR plates covered with optical film, using 
the described above PCR thermal cycler. As ligands 
peptide solutions of PIF (wt sequence), PIF
mut-1
, 
and PIF
mut-3
 at a concentration of 10 μM in buffer 
containing 10 mM HEPES-Na (pH 7.5) and 100 mM 
NaCl in a 50-μL volume was mixed with recombinant 
IDE protein (OriGene ID TP320700) at concentration 
of 1 μM or with equivalent amounts of DMSO. Final 
DMSO concentration was maintained at 4% (v/v). 
The environmentally sensitive dye, SYPRO Orange 
(Invitrogen, Carlsbad, CA), was used to monitor 
protein unfolding at a final arbitrary concentration of 
“6.25X” (the dye is sold as a DMSO stock marked 
“5000X”). Thermal unfolding was monitored at 0.5°C 
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intervals from 25°C to 85°C. To determine the melting 
temperature (or midpoint temperature of transition), 
Tm, for the protein, a Boltzmann model was used to 
fit protein unfolding curves (thermal melting profiles) 
(i.e., fluorescence intensity versus temperature) [42] 
using GraphPad Prism version 3.0. The raw data were 
transformed, fitted and normalized to have same lower 
and higher values, and the midpoint temperature of 
transition Tm was obtained and separately charted as Tm 
vs ligand type or ligand concentration, where more than 
one ligand concentrations were tested.
Chemicals, plasmids and antibodies
We purchased N-Ethylmaleimide (NEM) BioXtra, 
≥98% (HPLC) from Sigma-Aldrich (ID 24894398). 
PIF (MVRIKPGSANKPSDD) was provided by Bio-
Synthesis, Inc. (Lewisville, TX, USA). We purchased 
plasmids containing amyloid precursor protein (APP) 
from Addgene (pCAX APP 695 #30137). Anti-
IDE antibody (SAB2500529) was purchased from 
Sigma-Aldrich, anti-APP antibody (ALS16390) from 
Abgent and anti-Aβ17-24 antibody (SIG-39220) from 
BioLegend.
Culture of mouse neuroblastoma cell line 
neuro2a (N2a)
Mouse neuroblastoma cell line neuro2a (N2a) 
from ATCC was used as previously described [23]. 
Briefly, the cells were expanded in Dulbecco’s Modified 
EaglesMedium (DMEM; GIBCO Invitrogen), containing 
4.5g/Lglucose (GIBCO, Auckland, New Zealand), 
supplemented with 10% Fetal Bovine Serum (FBS; 
Sigma S. Louis, USA), 100 U/ml penicillin and 100 
μg/ml streptomycin. We kept the cells in a 5% CO
2
 and 
95% air atmosphere at 37°C. We used Trypsin-EDTA 
(0.05%; Thermo Fisher Scientific) to detach N2a cells 
from culture plates. We transfected N2a cells in a 48- well 
plate scale in complete medium without antibiotics at 
a density of ~8×104 per well. To prepare plasmid DNA 
APP-N2a transfection solution for each well, we mixed 
1 μg of empty vector or plasmid APP with 25μl OPTI-
MEM by gentle pipetting. In parallel, we mixed 1 μl 
Lipofectamine 2000 with 25μl OPTI-MEM. Following 5 
min of incubation at room temperature (RT), we mixed 
the two by gentle pipetting and incubated for 20 to 30 min 
at RT to allow DNA/lipid complexes to form. At the end 
of incubation, we used the 50μl transfection solution to 
re-suspend the cell pellet. After incubation at RT for 10 
min, we added regular growth medium to reach 500 μl 
of volume and we transferred the cell suspension to the 
culture plate. After 24-h incubation at 37°C in 5% CO
2
, 
we replaced the medium with fresh growth medium 
containing NEM 5 μM, or NEM and PIF 300 nM, 
(or PBS) respectively, followed by incubation for 48h. 
Proteins were then extracted and analyzed.
Protein isolation and western blotting
We isolated proteins using the QIAshredder and the 
Allprep DNA/RNA/Protein Mini Kits (Qiagen) according 
to the manufacturer’s protocol. Total protein concentration 
was measured by the bicinchoninic acid protein assay kit 
(Sigma-Aldrich). We separated protein by SDS-PAGE 
and transferred onto nitrocellulose membranes (Thermo 
Fisher Scientific), blocked with 5% BSA and analyzed 
with a Anti-IDE (1:500), anti-Aβ17-24 (1:300) and anti-
APP (1:300). We used HRP-coupled donkey as secondary 
antibodies (1:1’000; GE Healthcare Life Sciences). We 
detected binding by chemiluminescence using Amersham 
ECL Prime Western blotting reagent (GE Healthcare Life 
Sciences) on a Chemidoc XRS+ system from Bio-Rad 
Laboratories GmbH.
Statistical analysis
We used ImageJ software for pixel summation 
of individual bands. We corrected pixel intensities 
for background. We standardized protein intensities 
standardized to the corresponding β-actin bands. 
Theeffects of PIF in neuronal cells were analyzed by 
ANOVA followed by two tail t test setting significance 
at P<0.05.
Author contributions
SH, MM, and ERB designed the study. In-
vitro experiments were carried out by MS and MM. 
Bioinformatics were carried out by SH, KT and analyzed 
by MM and ERB. ERB, MM, and SH wrote the 
manuscript.
ACKNOWLEDGMENTS
We thank Amy Carter for valuable editorial 
assistance, and Moussa Barzani, Biosynthesis Tx, for 
generating the PIF reagents.
CONFLICTS OF INTEREST
No conflicts of interest to declare.
FUNDING
This work was supported University of Bern 
grant (CTU Grant) and BioIncept LLC funding. PIF is 
proprietary to BioIncept, LLC and ERB is Chief Scientist. 
SH and MM received an unrestricted BioInceot grant. No 
conflicts of interest to declare.
Oncotarget33894www.oncotarget.com
REFERENCES
1. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins 
RN, Beyreuther K. Neuronal origin of a cerebral amyloid: 
neurofibrillary tangles of Alzheimer’s disease contain the 
same protein as the amyloid of plaque cores and blood 
vessels. EMBO J. 1985; 4:2757–63.
2. Pivovarova O, Höhn A, Grune T, Pfeiffer AF, Rudovich 
N. Insulin-degrading enzyme: new therapeutic target 
for diabetes and Alzheimer’s disease? Ann Med. 2016; 
48:614–24.
3. Ruthirakuhan M, Herrmann N, Suridjan I, Abraham 
EH, Farber I, Lanctôt KL. Beyond immunotherapy: new 
approaches for disease modifying treatments for early 
Alzheimer’s disease. Expert Opin Pharmacother. 2016; 
17:2417–29.
4. Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures 
of human insulin-degrading enzyme reveal a new substrate 
recognition mechanism. Nature. 2006; 443:870–74.
5. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, 
Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude 
B, Charpentier G, et al. A genome-wide association study 
identifies novel risk loci for type 2 diabetes. Nature. 2007; 
445:881–85.
6. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme 
and amyloid-beta peptide in Alzheimer’s disease: review 
and hypothesis. Neurobiol Aging. 2006; 27:190–98.
7. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen 
S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, 
Craft S. Reduced hippocampal insulin-degrading enzyme 
in late-onset Alzheimer’s disease is associated with the 
apolipoprotein E-epsilon4 allele. Am J Pathol. 2003; 
162:313–19.
8. Rudovich N, Pivovarova O, Fisher E, Fischer-Rosinsky A, 
Spranger J, Möhlig M, Schulze MB, Boeing H, Pfeiffer AF. 
Polymorphisms within insulin-degrading enzyme (IDE) 
gene determine insulin metabolism and risk of type 2 
diabetes. J Mol Med (Berl). 2009; 87:1145–51.
9. Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, 
Leissring MA, Tang WJ, Charron MJ, Seeliger MA, 
Saghatelian A, Liu DR. Anti-diabetic activity of insulin-
degrading enzyme inhibitors mediated by multiple 
hormones. Nature. 2014; 511:94–98.
10. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau 
V, Rosner MR, Selkoe DJ. Neurons regulate extracellular 
levels of amyloid beta-protein via proteolysis by insulin-
degrading enzyme. J Neurosci. 2000; 20:1657–65.
11. Carrasquillo MM, Belbin O, Zou F, Allen M, Ertekin-Taner 
N, Ansari M, Wilcox SL, Kashino MR, Ma L, Younkin LH, 
Younkin SG, Younkin CS, Dincman TA, et al. Concordant 
association of insulin degrading enzyme gene (IDE) 
variants with IDE mRNA, Abeta, and Alzheimer’s disease. 
PLoS One. 2010; 5:e8764.
12. Zuo X, Jia J. Promoter polymorphisms which modulate 
insulin degrading enzyme expression may increase 
susceptibility to Alzheimer’s disease. Brain Res. 2009; 
1249:1–8.
13. Barnea ER. Insight into early pregnancy events: the 
emerging role of the embryo. Am J Reprod Immunol. 2004; 
51:319–22.
14. Barnea ER, Kirk D, Ramu S, Rivnay B, Roussev R, Paidas 
MJ. PreImplantation Factor (PIF) orchestrates systemic 
antiinflammatory response by immune cells: effect on 
peripheral blood mononuclear cells. Am J Obstet Gynecol. 
2012; 207:313.e1–11.
15. Stamatkin CW, Roussev RG, Stout M, Absalon-Medina V, 
Ramu S, Goodman C, Coulam CB, Gilbert RO, Godke RA, 
Barnea ER. PreImplantation Factor (PIF) correlates with early 
mammalian embryo development-bovine and murine models. 
Reprod Biol Endocrinol. 2011; 9:63.
16. Ramu S, Stamatkin C, Timms L, Ruble M, Roussev RG, 
Barnea ER. PreImplantation factor (PIF) detection in 
maternal circulation in early pregnancy correlates with 
live birth (bovine model). Reprod Biol Endocrinol. 2013; 
11:105.
17. Duzyj CM, Barnea ER, Li M, Huang SJ, Krikun G, 
Paidas MJ. Preimplantation factor promotes first trimester 
trophoblast invasion. Am J Obstet Gynecol. 2010; 203:402.
e1–4.
18. Roussev RG, Dons’koi BV, Stamatkin C, Ramu S, 
Chernyshov VP, Coulam CB, Barnea ER. Preimplantation 
factor inhibits circulating natural killer cell cytotoxicity 
and reduces CD69 expression: implications for recurrent 
pregnancy loss therapy. Reprod Biomed Online. 2013; 
26:79–87.
19. Paidas MJ, Krikun G, Huang SJ, Jones R, Romano M, 
Annunziato J, Barnea ER. A genomic and proteomic 
investigation of the impact of preimplantation factor on 
human decidual cells. Am J Obstet Gynecol. 2010; 202:459 
e451-458. https://doi.org/10.1016/j.ajog.2010.03.024.
20. Weiss L, Or R, Jones RC, Amunugama R, JeBailey L, 
Ramu S, Bernstein SA, Yekhtin Z, Almogi-Hazan O, 
Shainer R, Reibstein I, Vortmeyer AO, Paidas MJ, et al. 
Preimplantation factor (PIF*) reverses neuroinflammation 
while promoting neural repair in EAE model. J Neurol Sci. 
2012; 312:146–57.
21. Migliara G, Mueller M, Piermattei A, Brodie C, Paidas 
MJ, Barnea ER, Ria F. PIF* promotes brain re-myelination 
locally while regulating systemic inflammation- clinically 
relevant multiple sclerosis M.smegmatis model. 
Oncotarget. 2017; 8:21834-21851. https://doi.org/10.18632/
oncotarget.15662.
22.  Mueller M, Zhou J, Yang L, Gao Y, Wu F, Schoeberlein A, 
Surbek D, Barnea ER, Paidas M, Huang Y. PreImplantation 
factor promotes neuroprotection by targeting microRNA let-
7. Proc Natl Acad Sci USA. 2014; 111:13882–87.
Oncotarget33895www.oncotarget.com
23. Mueller M, Schoeberlein A, Zhou J, Joerger-Messerli M, 
Oppliger B, Reinhart U, Bordey A, Surbek D, Barnea 
ER, Huang Y, Paidas M. PreImplantation Factor bolsters 
neuroprotection via modulating Protein Kinase A and 
Protein Kinase C signaling. Cell Death Differ. 2015; 
22:2078–86.
24. Barnea ER, Almogi-Hazan O, Or R, Mueller M, Ria F, 
Weiss L, Paidas MJ. Immune regulatory and neuroprotective 
properties of preimplantation factor: from newborn to adult. 
Pharmacol Ther. 2015; 156:10–25.
25. Weiss L, Bernstein S, Jones R, Amunugama R, Krizman D, 
Jebailey L, Almogi-Hazan O, Yekhtin Z, Shiner R, Reibstein 
I, Triche E, Slavin S, Or R, Barnea ER. Preimplantation 
factor (PIF) analog prevents type I diabetes mellitus 
(TIDM) development by preserving pancreatic function in 
NOD mice. Endocrine. 2011; 40:41–54.
26. Chen YC, Rivera J, Fitzgerald M, Hausding C, Ying YL, 
Wang X, Todorova K, Hayrabedyan S, Barnea ER, Peter 
K. PreImplantation factor prevents atherosclerosis via its 
immunomodulatory effects without affecting serum lipids. 
Thromb Haemost. 2016; 115:1010–24.
27. Azar Y, Shainer R, Almogi-Hazan O, Bringer R, Compton 
SR, Paidas MJ, Barnea ER, Or R. Preimplantation factor 
reduces graft-versus-host disease by regulating immune 
response and lowering oxidative stress (murine model). Biol 
Blood Marrow Transplant. 2013; 19:519–28.
28. hainer R, Almogi-Hazan O, Berger A, Hinden L, 
Mueller M, Brodie C, Simillion C, Paidas M, Barnea 
ER, Or R. PreImplantation factor (PIF) therapy provides 
comprehensive protection against radiation induced 
pathologies. Oncotarget. 2016; 7:58975-58994. https://doi.
org/10.18632/oncotarget.10635.
29. Vingtdeux V, Chandakkar P, Zhao H, Blanc L, Ruiz S, 
Marambaud P. CALHM1 ion channel elicits amyloid-β 
clearance by insulin-degrading enzyme in cell lines and in 
vivo in the mouse brain. J Cell Sci. 2015; 128:2330–38.
30. Barnea ER, Lubman DM, Liu YH, Absalon-Medina V, 
Hayrabedyan S, Todorova K, Gilbert RO, Guingab J, Barder 
TJ. Insight into PreImplantation Factor (PIF*) mechanism 
for embryo protection and development: target oxidative 
stress and protein misfolding (PDI and HSP) through 
essential RIKP [corrected] binding site. PLoS One. 2014; 
9:e100263.
31. Hersh LB. The insulysin (insulin degrading enzyme) 
enigma. Cell Mol Life Sci. 2006; 63:2432–34.
32. Malito E, Ralat LA, Manolopoulou M, Tsay JL, Wadlington 
NL, Tang WJ. Molecular bases for the recognition of short 
peptide substrates and cysteine-directed modifications of 
human insulin-degrading enzyme. Biochemistry. 2008; 
47:12822–34.
33. Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-
Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring 
MA, Tang WJ. Structure of substrate-free human insulin-
degrading enzyme (IDE) and biophysical analysis of ATP-
induced conformational switch of IDE. J Biol Chem. 2007; 
282:25453–63.
34. Niesen FH, Berglund H, Vedadi M. The use of differential 
scanning fluorimetry to detect ligand interactions that 
promote protein stability. Nat Protoc. 2007; 2:2212–21.
35. O'Brien C, Barnea ER, Martin P, Levy C, Sharabi E, 
Bhamidimarri K, Martin K, Arosemena L, Schiff ER. 
Randomized, Double-Blind, Placebo-Controlled, Single 
Ascending Dose Trial of Synthetic Preimplantation Factor 
in Autoimmune Hepatitis. Hepatology Communications. 
2018. Ahead of Print.
36. Zemla A. LGA: A method for finding 3D similarities in 
protein structures. Nucleic Acids Res. 2003; 31:3370–74.
37. Zemla A, Geisbrecht B, Smith J, Lam M, Kirkpatrick B, 
Wagner M, Slezak T, Zhou CE. STRALCP—structure 
alignment-based clustering of proteins. Nucleic Acids Res. 
2007; 35:e150.
38. Barnea ER, Kirk D, Todorova K, McElhinney J, 
Hayrabedyan S, Fernández N. PIF direct immune 
regulation: blocks mitogen-activated PBMCs proliferation, 
promotes TH2/TH1 bias, independent of Ca(2+). 
Immunobiology. 2015; 220:865–75.
39. London N, Raveh B, Cohen E, Fathi G, Schueler-Furman 
O. Rosetta FlexPepDock web server—high resolution 
modeling of peptide-protein interactions. Nucleic Acids 
Res. 2011; 39:W249-53.
40. Shatsky M, Nussinov R, Wolfson HJ. A method for 
simultaneous alignment of multiple protein structures. 
Proteins. 2004; 56:143–56.
41. Kurcinski M, Jamroz M, Blaszczyk M, Kolinski A, Kmiecik 
S. CABS-dock web server for the flexible docking of 
peptides to proteins without prior knowledge of the binding 
site. Nucleic Acids Res. 2015; 43:W419-24.
42. Ericsson UB, Hallberg BM, Detitta GT, Dekker N, 
Nordlund P. Thermofluor-based high-throughput stability 
optimization of proteins for structural studies. Anal 
Biochem. 2006; 357:289–98.
